ClinicalTrials.gg
Status unknownNCT02846207Updated Feb 12, 2018

Yiqi Huoxue Demolition and Recipes on Recovery Stage of Cerebral Infarction

An interventional study of Yiqi huoxue and Yiqi group in Cerebral Infarction, sponsored by Dongfang Hospital Beijing University of Chinese Medicine. Status unknown at 3 sites in China. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-02-12.

Sponsored by Dongfang Hospital Beijing University of Chinese Medicine · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Cerebral Infarction with a site in China — 16 open to participants now, 18 under way, 3 of them phase 3. Cerebral Infarction · China.

Planned enrollment
13th of 37
360 · median 210
Started
2016
with 2 others
No phase
13 of 58
4 open now
Registered
16th of 58
by date

Among the 58 studies in Cerebral Infarction with a site in China, this one is the 13th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2016, is one of 13 with no phase, and was the 16th registered.

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

Browse Cerebral Infarction studies →

Open to participants now

16 of the 58 studies in Cerebral Infarction with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Cerebral Infarction with a site in China, or all of them as a file.
02

Study summary

This clinical research is based on the fundamentals of using Chinese medicine, which will improve Qi and promote blood circulation, to treat patients in the recuperating stages of cerebral infarction with deficiency in Qi and blood stasis syndrome. By assimilating Chinese medical theory, this research aims to study the biological basics of the stroke and the cause for the deficiency in Qi and blood stasis syndrome; explore the therapeutic mechanism of the treatment methods; as well as ascertaining the relationship between Qi, blood and blood vessels.

Read the detailed description

Cerebral infarction, or ischemic stroke, is a common yet challenged illness with four telltale signs (high occurrence rate, high incapacitate rate, high mortality rate, and high recurrence rate), posing not only a threat to a man's health and life, but also imposing a burden to the society and his loved ones. As such, seeking a cure has always been the hot topic in this field of research. With regard to the illness' high incapacitate and recurrence rates, it has become apparent that the treatment methods used in the recuperating stages of stroke are very significant to the patient, allowing him the chance to regain his health and increase his quality of life. In Chinese medical terms, the pathogenesis key of stroke is a deficiency in the vitals of the body coupled with superficiality extremities. As such, in the recuperating stage of the stroke, a lack of Qi accompanied with blood stasis syndrome is often observed. Hence, improving Qi and promoting blood circulation is essential during treatment. Research further supports that this treatment method is highly effective in treating cerebral infarction, but the mechanism involved is still incomprehensible, largely due to the fact that the pathology of cerebral infraction is highly complicated, and that Chinese medicine is multi-leveled, multi-channeled, with multi-targets. To further study the relationship of Qi and blood in cerebral infraction, patients in the recuperating stages with deficiency in Qi and blood stasis underwent observation in a double blind clinical research. The patients were sorted in random into groups: improving Qi group, promoting blood circulation group, improving Qi and promoting blood circulation group, and the control group. Each group of patients was given the standard Western medicine treatment, coupled with Chinese medicine treatments with respect to their sorted groupings. The treatment lasts for 12 weeks and 360 clinical cases were studied. Testing methods used include enzyme linked immunosorbent assay, Western Blot, FQ RT-PCR, LC-MS, and radiology. Through the relations between Neurotransmitter - endocrine hormone - immune cytokine network, blood rheology, vascular structure and endothelial function, interactions involving vasoactive substances with vascular endothelium and blood cells, it is hoped that the biological basis of cerebral infraction's deficiency in Qi and blood stasis syndrome can be deciphered. This will aid in the understanding of the whole process of causing the syndrome, deciphering the therapeutic mechanism involved during treatment, as well as determining the relationship between Qi, blood and blood vessels.

03

Conditions studied

  • Cerebral Infarction

Browse trials for

Keywords

  • cerebral infarction
  • syndrome of qi deficiency and blood stasis
  • Buyanghuanwu decoction
  • clinical effects and mechanisms
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In accordance to the Western medicine diagnostic criteria for atherosclerotic thrombotic cerebral infarction;
  2. In accordance to the Chinese medicine diagnostic criteria for stroke, with deficiency in Qi and blood stasis syndrome;
  3. In accordance to Stroke's diagnostic scale factor standards: asthenic Qi syndrome ≥ 10 points, blood stasis ≥ 10 points;
  4. Within the recuperating stage of the illness (2 weeks to 6 months);
  5. National Institutes of Health Stroke Scale (NIHSS) with a score of 3-22 points;
  6. Ages within 35-80;
  7. Signature of consent to participate in the research.

Exclusion criteria

Exclusion Criteria:

  1. Patients suffering from (TIA), subarachnoid haemorrhage and cerebral haemorrhage;
  2. Patients suffering from cerebral embolism due to superficiality extremities caused by rheumatic heart disease, coronary heart disease and other heart diseases coupled with atrial fibrillation; stroke patients caused by brain tumor, head trauma, blood diseases, etc;
  3. Pregnant women or women planning for pregnancy, women with positive urine pregnancy test, and lactating women;
  4. Patients with severe hepatic and renal dysfunction, severe disease of the hematopoietic system, highly active ulcer and bleeding tendency, severe disease of the endocrine system, severe bone and joint disease, and arrhythmia patients with great clinical significance;
  5. Patients with mental impairment, or mental disability, or severely deaf, or unconscious, or being uncooperative during inspection;
  6. Patients with known allergies to the medicine used, as well as overly sensitive patients;
  7. Patients that underwent clinical trials within the past 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Yiqi huoxue group

    Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

    Drug: Yiqi huoxue

  • Experimental
    Yiqi group

    Astragalus 60g. Oral administration, twice one day, for 12weeks.

    Drug: Yiqi group

  • Experimental
    Huoxue group

    Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

    Drug: Huoxue group

  • Placebo comparator
    placebo group

    dextrin, Oral administration, twice one day, for 12weeks.

    Drug: placebo

Interventions

  • DrugYiqi huoxue

    Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

    Also known as: tonifying Qi and activating blood

  • DrugYiqi group

    Astragalus 60g.Oral administration, twice one day, for 12weeks.

    Also known as: tonifying qi, benefiting qi

  • DrugHuoxue group

    Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

    Also known as: activating blood

  • Drugplacebo

    Dextrin,oral administration, twice one day, for 12weeks.

    Also known as: a soothing restorative agency

06

What researchers measure

Primary outcomes

  1. National Institute of Health Stroke Scale

    NIHSS

    Time frame: 12 weeks

Secondary outcomes

  1. Modified Rankin scale

    0-5scales

    Time frame: 12 weeks

  2. Barthel index

    0-100scales

    Time frame: 12 weeks

07

Study locations

3 of 3 sites recruiting
  • Dongfang Hospital
    Beijing, Beijing 100078, China
    Recruiting
  • Xingtai People's Hospital
    Xingtai, Hebei 054001, China
    Recruiting
    • Wang Jianhua, PhD,MD · Contact
  • The First Affiliated Hospital of Henan Univerisity of TCM
    Zhengzhou, Henan 450000, China
    Recruiting
    • Liu Xiangzhe, PhD,MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Dec 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2016
First posted
Jul 27, 2016
Start
Mar 2016
Primary completionEst.
Dec 2019
CompletionEst.
Dec 2019
Last update
Feb 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02846207
Lead sponsor
Dongfang Hospital Beijing University of Chinese Medicine
Collaborators
Xingtai People's Hospital
Responsible party
Sponsor
First posted
Jul 27, 2016
Start date
Mar 2016
Primary completion
Dec 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Feb 12, 2018

Study contacts

Guo Ronguan, PhD,MD
Contact
Dfguorongjuan@163.com
+86 10 67689634
Guo Rongjuan, PhD,MD
Contact
Dfguorongjuan@163.com
+86 10 67689634
Liu Xiangzhe, PHD,MD
principal investigator · The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Wang Jianhua, PHD,MD
principal investigator · Xingtai People's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion